Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans

Susan E. Steck, Allison M. Chalecki, Paul Miller, Jason Conway, Gregory L. Austin, James W. Hardin, Craig D. Albright, Philippe Thuillier

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Conjugated linoleic acid (CLA) alters body composition in animal models, but few studies have examined the effects of CLA supplementation on body composition and clinical safety measures in obese humans. In the present study, we performed a randomized, double-blind, placebo-controlled trial to examine the changes in body composition and clinical laboratory values following CLA (50:50 ratio of cis-9, trans-11 and trans-10, cis-12 isomers) supplementation for 12 wk in otherwise healthy obese humans. Forty-eight participants (13 males and 35 females) were randomized to receive placebo (8 g safflower oil/d), 3.2 g/d CLA, or 6.4 g/d CLA for 12 wk. Changes in body fat mass and lean body mass were determined by dual-energy X-ray absorptiometry. Resting energy expenditure was assessed by indirect calorimetry. Clinical laboratory values and adverse-event reporting were used to monitor safety. Lean body mass increased by 0.64 kg in the 6.4 g/d CLA group (P <0.05) after 12 wk of intervention. Significant decreases in serum HDL-cholesterol and sodium, hemoglobin, and hematocrit, and significant increases in serum alkaline phosphatase, C-reactive protein, and IL-6, and white blood cells occurred in the 6.4 g/d CLA group, although all values remained within normal limits. The intervention was well tolerated and no severe adverse events were reported, although mild gastrointestinal adverse events were reported in all treatment groups. In conclusion, whereas CLA may increase lean body mass in obese humans, it may also increase markers of inflammation in the short term.

Original languageEnglish (US)
Pages (from-to)1188-1193
Number of pages6
JournalJournal of Nutrition
Volume137
Issue number5
StatePublished - May 2007
Externally publishedYes

Fingerprint

Conjugated Linoleic Acids
lean body mass
conjugated linoleic acid
Body Composition
body composition
placebos
Placebos
Safflower Oil
Safety
Indirect Calorimetry
resting energy expenditure
safflower oil
dual-energy X-ray absorptiometry
C-reactive protein
Photon Absorptiometry
calorimetry
Serum
Hematocrit
high density lipoprotein cholesterol
interleukin-6

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Steck, S. E., Chalecki, A. M., Miller, P., Conway, J., Austin, G. L., Hardin, J. W., ... Thuillier, P. (2007). Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. Journal of Nutrition, 137(5), 1188-1193.

Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. / Steck, Susan E.; Chalecki, Allison M.; Miller, Paul; Conway, Jason; Austin, Gregory L.; Hardin, James W.; Albright, Craig D.; Thuillier, Philippe.

In: Journal of Nutrition, Vol. 137, No. 5, 05.2007, p. 1188-1193.

Research output: Contribution to journalArticle

Steck, SE, Chalecki, AM, Miller, P, Conway, J, Austin, GL, Hardin, JW, Albright, CD & Thuillier, P 2007, 'Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans', Journal of Nutrition, vol. 137, no. 5, pp. 1188-1193.
Steck SE, Chalecki AM, Miller P, Conway J, Austin GL, Hardin JW et al. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. Journal of Nutrition. 2007 May;137(5):1188-1193.
Steck, Susan E. ; Chalecki, Allison M. ; Miller, Paul ; Conway, Jason ; Austin, Gregory L. ; Hardin, James W. ; Albright, Craig D. ; Thuillier, Philippe. / Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. In: Journal of Nutrition. 2007 ; Vol. 137, No. 5. pp. 1188-1193.
@article{f84e59ab93b645d8a2c9185817ab8dbc,
title = "Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans",
abstract = "Conjugated linoleic acid (CLA) alters body composition in animal models, but few studies have examined the effects of CLA supplementation on body composition and clinical safety measures in obese humans. In the present study, we performed a randomized, double-blind, placebo-controlled trial to examine the changes in body composition and clinical laboratory values following CLA (50:50 ratio of cis-9, trans-11 and trans-10, cis-12 isomers) supplementation for 12 wk in otherwise healthy obese humans. Forty-eight participants (13 males and 35 females) were randomized to receive placebo (8 g safflower oil/d), 3.2 g/d CLA, or 6.4 g/d CLA for 12 wk. Changes in body fat mass and lean body mass were determined by dual-energy X-ray absorptiometry. Resting energy expenditure was assessed by indirect calorimetry. Clinical laboratory values and adverse-event reporting were used to monitor safety. Lean body mass increased by 0.64 kg in the 6.4 g/d CLA group (P <0.05) after 12 wk of intervention. Significant decreases in serum HDL-cholesterol and sodium, hemoglobin, and hematocrit, and significant increases in serum alkaline phosphatase, C-reactive protein, and IL-6, and white blood cells occurred in the 6.4 g/d CLA group, although all values remained within normal limits. The intervention was well tolerated and no severe adverse events were reported, although mild gastrointestinal adverse events were reported in all treatment groups. In conclusion, whereas CLA may increase lean body mass in obese humans, it may also increase markers of inflammation in the short term.",
author = "Steck, {Susan E.} and Chalecki, {Allison M.} and Paul Miller and Jason Conway and Austin, {Gregory L.} and Hardin, {James W.} and Albright, {Craig D.} and Philippe Thuillier",
year = "2007",
month = "5",
language = "English (US)",
volume = "137",
pages = "1188--1193",
journal = "Journal of Nutrition",
issn = "0022-3166",
publisher = "American Society for Nutrition",
number = "5",

}

TY - JOUR

T1 - Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans

AU - Steck, Susan E.

AU - Chalecki, Allison M.

AU - Miller, Paul

AU - Conway, Jason

AU - Austin, Gregory L.

AU - Hardin, James W.

AU - Albright, Craig D.

AU - Thuillier, Philippe

PY - 2007/5

Y1 - 2007/5

N2 - Conjugated linoleic acid (CLA) alters body composition in animal models, but few studies have examined the effects of CLA supplementation on body composition and clinical safety measures in obese humans. In the present study, we performed a randomized, double-blind, placebo-controlled trial to examine the changes in body composition and clinical laboratory values following CLA (50:50 ratio of cis-9, trans-11 and trans-10, cis-12 isomers) supplementation for 12 wk in otherwise healthy obese humans. Forty-eight participants (13 males and 35 females) were randomized to receive placebo (8 g safflower oil/d), 3.2 g/d CLA, or 6.4 g/d CLA for 12 wk. Changes in body fat mass and lean body mass were determined by dual-energy X-ray absorptiometry. Resting energy expenditure was assessed by indirect calorimetry. Clinical laboratory values and adverse-event reporting were used to monitor safety. Lean body mass increased by 0.64 kg in the 6.4 g/d CLA group (P <0.05) after 12 wk of intervention. Significant decreases in serum HDL-cholesterol and sodium, hemoglobin, and hematocrit, and significant increases in serum alkaline phosphatase, C-reactive protein, and IL-6, and white blood cells occurred in the 6.4 g/d CLA group, although all values remained within normal limits. The intervention was well tolerated and no severe adverse events were reported, although mild gastrointestinal adverse events were reported in all treatment groups. In conclusion, whereas CLA may increase lean body mass in obese humans, it may also increase markers of inflammation in the short term.

AB - Conjugated linoleic acid (CLA) alters body composition in animal models, but few studies have examined the effects of CLA supplementation on body composition and clinical safety measures in obese humans. In the present study, we performed a randomized, double-blind, placebo-controlled trial to examine the changes in body composition and clinical laboratory values following CLA (50:50 ratio of cis-9, trans-11 and trans-10, cis-12 isomers) supplementation for 12 wk in otherwise healthy obese humans. Forty-eight participants (13 males and 35 females) were randomized to receive placebo (8 g safflower oil/d), 3.2 g/d CLA, or 6.4 g/d CLA for 12 wk. Changes in body fat mass and lean body mass were determined by dual-energy X-ray absorptiometry. Resting energy expenditure was assessed by indirect calorimetry. Clinical laboratory values and adverse-event reporting were used to monitor safety. Lean body mass increased by 0.64 kg in the 6.4 g/d CLA group (P <0.05) after 12 wk of intervention. Significant decreases in serum HDL-cholesterol and sodium, hemoglobin, and hematocrit, and significant increases in serum alkaline phosphatase, C-reactive protein, and IL-6, and white blood cells occurred in the 6.4 g/d CLA group, although all values remained within normal limits. The intervention was well tolerated and no severe adverse events were reported, although mild gastrointestinal adverse events were reported in all treatment groups. In conclusion, whereas CLA may increase lean body mass in obese humans, it may also increase markers of inflammation in the short term.

UR - http://www.scopus.com/inward/record.url?scp=34247846071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247846071&partnerID=8YFLogxK

M3 - Article

C2 - 17449580

AN - SCOPUS:34247846071

VL - 137

SP - 1188

EP - 1193

JO - Journal of Nutrition

JF - Journal of Nutrition

SN - 0022-3166

IS - 5

ER -